“Significant overlap” between figures spurs note of concern for 13-year-old retinoblastoma paper

AmJPatholThe American Journal of Pathology has posted a note of concern to a 2002 paper about retinoblastoma after discovering two sets of figures “share significant overlap… suggesting that they did not originate from different specimens.”

The overlap was “simultaneously brought to the attention of the Editors” by both the corresponding author and a “concerned reader.”

The paper examined the role of a transcription factor called NF-kappaB in driving retinoblastoma, and suggested that inhibiting the molecule’s activity could be a therapeutic strategy.

The authors attribute the overlap to “an inadvertent misidentification of the original files at the stage of image capture.” They add that they “sincerely regret this inadvertent error;” because other data in the paper show “concordant results,” they stand by the paper’s findings.

Here’s the note:

Continue reading “Significant overlap” between figures spurs note of concern for 13-year-old retinoblastoma paper

Weekend reads: Sexism from a Nobel laureate; publisher deception; irreproducibility’s price tag

booksThe week at Retraction Watch featured the story behind a Nature retraction, and the retraction of a paper by a pioneer in the field of exosome research. Here’s what was happening elsewhere: Continue reading Weekend reads: Sexism from a Nobel laureate; publisher deception; irreproducibility’s price tag

Nature retraction, resignation result after lung cancer cell lines “cannot be those specified”

cover_natureUpon realizing they had experienced a case of mistaken cell-line identity, the authors of a 2014 Nature paper on lung cancer think “it prudent to retract pending more thorough investigation,” as they explain in a notice published Wednesday.

The problem seems to stem from more than just honest error, according to corresponding author Julian Downward, a scientist at the Francis Crick Institute in the UK.

In a 1,215 word statement, sent to us via the Director of Research Communications and Engagement at Cancer Research UK, which funds Downward’s research, Downward told us the backstory not presented in the journal’s retraction note:

Continue reading Nature retraction, resignation result after lung cancer cell lines “cannot be those specified”

Cancer paper pulled due to “identical text” from one published 6 days prior; author objects

ClinCancRes_ak16Clinical Cancer Research is retracting a paper on the immunosuppressive effects of glioma due to “evidence of duplicate and/or redundant publication.”

According to the retraction notice, the 2010 paper bore exceeding similarities to another one published by the same group of researchers six days prior. That second paper appeared in Molecular Cancer Therapeutics, which – like Clinical Cancer Research — is published by the American Association for Cancer Research. Apparently, a reader tipped off the AACR about the similarity.

The corresponding author on both papers, however, has objected to the decision: Continue reading Cancer paper pulled due to “identical text” from one published 6 days prior; author objects

“Evidence of data duplication” infects lung inflammation paper from Harvard and Yale

IAIA team of Harvard and Yale biologists have retracted an Infection and Immunity paper due to data duplication.

After the duplication came to light, the erroneous figures were corrected using original data, but the results affected “some of the manuscript’s conclusions.” An ethics panel subsequently recommended retraction, according to the journal, and the authors agreed.

The paper, “NOD2 Signaling Contributes to Host Defense in the Lungs against Escherichia coli Infection,” analyzed the role of the gene NOD2 in the lung inflammatory response against the bacteria Escherichia coli. It has been cited by 15 other papers, according to Thomson Scientific’s Web of Knowledge.

Figure 2B of the paper was previously corrected in 2012, but the retraction is for data duplication in figures 5F and 6A. Here’s the full retraction note: Continue reading “Evidence of data duplication” infects lung inflammation paper from Harvard and Yale

“Significant concerns” and formal investigation unwind Nature Nanotech sequencing paper

NatureNanoFollowing “significant concerns” raised by outside researchers and a formal university investigation, a group of authors in Taiwan has retracted a Nature Nanotechnology paper on DNA sequencing after they “could not reproduce the results of the work,” or even provide “a complete set of raw data for the original experiments.”

The paper, “DNA sequencing using electrical conductance measurements of a DNA polymerase,” describes a technology to sequence single DNA molecules — a technique that the authors, all based at National Chiao Tung University in Taiwan, suggest could be used to “cheaply and quickly” sequence DNA.

Concerns about the paper’s data were first raised in May 2013 by the community, according to an editorial from the journal. Then, the journal asked the university to investigate, says “Notes on a retraction”: Continue reading “Significant concerns” and formal investigation unwind Nature Nanotech sequencing paper

Fungus among us, but what kind? Typing error spawns retraction for mushroom paper

natprodresAs every mushroom lover knows, weekend mycology is no sport for the lily-livered. Tasty species often look awfully like their deadly cousins. Turns out, typing can even be problematic for the experts.

Natural Products Research is retracting a 2014 paper on shelf fungus because… well, it wasn’t about shelf fungus after all.

The paper, “Chemical constituents: water-soluble vitamins, free amino acids and sugar profile from Ganoderma adspersum,” was written by Ibrahim Kivrak, a food chemist at Mugla Sitki Kocman University in Mugla, Turkey. It analyzed the nutritional components of G. adspersum, and found, per the abstract:

Continue reading Fungus among us, but what kind? Typing error spawns retraction for mushroom paper

Pressure to publish not to blame for misconduct, says new study

plosoneA new study suggests that much of what we think about misconduct — including the idea that it is linked to the unrelenting pressure on scientists to publish high-profile papers — is incorrect.

In a new paper out today in PLOS ONE [see update at end of post], Daniele Fanelli, Rodrigo Costas, and Vincent Larivière performed a retrospective analysis of retractions and corrections, looking at the influence of supposed risk factors, such as the “publish or perish” paradigm. The findings appeared to debunk the influence of that paradigm, among others:

Continue reading Pressure to publish not to blame for misconduct, says new study

“I hold my hands up”: PubPeer criticisms spark a biochemist’s offer to retract

MPIn a back-and-forth on PubPeer, a researcher appears to have offered to retract a paper after commenters challenged the use of identical control bands on a gel.

A person writing as Virginia Commonwealth University biochemist Paul Dent admitted the control bands of his 2007 Molecular Pharmacology paper, “Human Chorionic Gonadotropin Modulates Prostate Cancer Cell Survival after Irradiation or HMG CoA Reductase Inhibitor Treatment,” were duplicated “for comparison purposes,” but stated he was “in no way attempting to ‘intentionally manipulate the data.’”

In response, Dent appeared to offer to pull the paper, about using a hormone to help kill prostate cancer cells:

Continue reading “I hold my hands up”: PubPeer criticisms spark a biochemist’s offer to retract

Exosome pioneer’s paper retracted after investigation finds “multiple” faked figures

JImmunolThe Journal of Immunology is retracting a 2006 article about the role of exosomes in pregnancy at the behest of the University of Louisville in Kentucky, following a misconduct investigation that “determined multiple figures” in the paper were falsified.

First author Douglas Taylor is a pioneer in exosome biology, having discovered the release of exosomes from tumor cells in the 1970s.

The retracted paper identified “significant quantitative and qualitative differences in released exosomes” in the placentas of fetuses delivered prematurely compared to those delivered without complications at term, particularly relating to immune regulation.  It has been cited 150 times, according to Thomson Scientific’s Web of Knowledge.

Here’s the retraction note (which is paywalled – tsk, tsk): Continue reading Exosome pioneer’s paper retracted after investigation finds “multiple” faked figures